Since April 1, noninvasive prenatal testing, provided by three university genetic centers, is available to all pregnant women in the Netherlands for €175 as part of the TRIDENT-2 study.
SeraCare is licensing UCSF's T21, T18, and T13 trophoblast cell line materials to develop NIPT reference materials.
The firm said in an SEC document that it plans to offer 6.25 million shares and expects net proceeds of up to $103.3 million.
In addition to offering NIPTs, Natera is eyeing the cancer diagnostics space.
The companies reached an exclusive deal to provide Natera's Panorama NIPT in the Indian market.
NEW YORK (GenomeWeb) – Mount Sinai Services today announced a distribution deal with Illumina to offer the Verifi non-invasive prenatal test in Ontario.
NEW YORK (GenomeWeb News) – The New York Department of Health has approved Ariosa Diagnostics to offer its non-invasive prenatal test to state residents, the company said today.
NEW YORK (GenomeWeb News) – Natera today announced a US distribution deal with pathology services provider ProPath for Natera's Panorama non-invasive prenatal screening test.
NEW YORK (GenomeWeb News) – Natera today announced that New York has issued a permit for the company's CLIA laboratory, allowing Natera to offer its preconception and prenatal tests to expecting parents in the state.
This article has been updated from a previous version to include information provided by a Novartis spokesperson.
Technology Review reports that 2017 was the year of consumer genetic testing and that it could spur new analysis companies.
A phylogenetic analysis indicates two venomous Australian spiders are more closely related than thought, the International Business Times reports.
In Science this week: CRISPR-based approach for recording cellular events, and more.
A new company says it will analyze customers' genes to find them a suitable date, though Smithsonian magazine says the science behind it might be shaky.